Choice Reversible Sterilization Device
- User: Female
- Hormonal: Non-Hormonal
-
Delivery type:
- Fallopian Tube
-
Intended Duration:
- Permanent
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): Choice, Máxima Medisch Centrum
Details
-
Mechanism of Action:
- Tubal Occlusion
- Inactive Materials: Nitinol, Ceramics
- Regimen: Single Placement
- MPT: Not Potential MPT
- Promising Attributes: Developers indicate that their device could be implanted a single time and allow users to choose whether to open or close the valve to either provide contraceptive protection or allow for egg fertilization
Product Status
Active/Recent Pre-Clinical Development
History
2018: Choice is founded to develop a mechanical valve that can be placed in the fallopian tube via catheter to be "switched on" when the user wants contraceptive protection and "switched off" when the user wants to become pregnant.
2021: US and EU patents granted for implantable tube valve
2024: In-vitro rabbit testing confirms device stays in place through strong muscle contraction of the reproductive system. Developer indicates that pre-hysterectomy testing in humans is next planned step.
2025: Choice announces intent to conduct additional pre-clinical evaluation throughout 2026 and 2027, with clinical evaluation initiating in 2028. Their clinical plan includes pivotal trials of 400-500 women across 12 hospitals.